{
  "id": 10441244,
  "title": "Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor",
  "url": "https://urgent.news/2026/09/28/merck-signs-2-13-bln-license-deal-with-scibrunch-therapeutics-for",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T12:02:47.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/merck-signs-213-bln-license-deal-scibrunch-therapeutics-kras-g12d-inhibitor"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Merck signs up to $2.13B license deal with SciBrunch",
        "url": "https://urgent.news/2026/09/28/merck-signs-up-to-2-13b-license-deal-with-scibrunch",
        "published": "2026-09-28T11:48:32.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}